Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)

Overview of attention for article published in npj Breast Cancer, October 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#22 of 610)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 151 X posts from 126 X users, with an upper bound of 276,234 followers.

RT @drsarahsam: Newer ADCs are getting better at penetration into the brain and CSF. This is huge and we need to expand on this in future…

RT @PTarantinoMD: More (impressive) data on the intracranial activity of T-DXd. Real-world cohort from Japan, including 104 patients with H…

RT @ElisaAgostinett: Results of ROSET-BM trial are now published in @Nature_NPJ Breast - important data on activity of T-DXd in patients wi…

RT @ElisaAgostinett: Results of ROSET-BM trial are now published in @Nature_NPJ Breast - important data on activity of T-DXd in patients wi…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 147 additional X posts.